Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That Continue reading QIDP Drug Update – Part 2: Categories of Interest
At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug
For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let’s take Melinta’s statement [1] at face value according to which the single 900 mg dose of delafloxacin failed because of Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (2)
Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg [1]. In Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)
The treatment history of N. gonorrhoeae makes for fascinating reading. This organism has always been able to keep the upper hand in the war of bug versus drug. Once susceptible to sulfa drugs, to penicillin, tetracyclines and fluoroquinolones, it sequentially Continue reading A GO / NO GO decision: Delafloxacin Stumbles in Gonorrhea Study